Health for Humanity 2020 Goals
Health for Humanity 2020 Goals

At Johnson & Johnson, we aspire to profoundly change the trajectory of health for humanity. Our Health for Humanity 2020 Goals, underpinned by 16 targets, focus our citizenship and sustainability efforts where we believe Johnson & Johnson can achieve the greatest impact. The goals underscore and reflect our long-term commitment to delivering sustainable social, environmental and economic change across our Company and extended value chain by leveraging the power of our people, expertise, and global partnerships.

Achieving our 2020 Goals is integral to Johnson & Johnson’s long-term success. We consider them to be the Key Performance Indicators of our citizenship and sustainability approach and have processes in place to measure and track progress. We report out on our progress annually, including independent review and assurance of our progress and associated data.

Following is our Scorecard2 that provides an update on progress we have made to-date against our 2020 Goals.

On track: expected to meet the Goal by 2020
In progress: so far progressing more slowly than expected; plans are in place to meet the Goal by 2020
Off track: not progressing as expected; currently at risk of not meeting the Goal by 2020

Health for Humanity 2020 Goals Scorecard
Target Progress against 2020 Targets (Cumulative) Notable Status
Develop and deliver innovative, lifechanging solutions to address the world’s major health challenges.
Deliver innovative healthcare access and training programs that impact a billion lives in underserved areas.*
Collaborate with government, nonprofit and private sector to foster new models of health that improve economic well-being and healthcare in key emerging markets.
Fully integrate sustainable design solutions into our product innovation processes.
Reduce our impacts on climate and water resources.
Collaborate with our suppliers to accelerate environmental and social improvements across the value chain.
Empower and engage the Johnson & Johnson family of employees to become the healthiest workforce.
2. All progress update figures have been rounded.
* “Underserved” refers to populations that are disadvantaged because of ability to pay, ability to access care, ability to access comprehensive healthcare, or other disparities for reasons of race, religion, language group or social status.
** After re-evaluating the progress measurement methodology for this target, we concluded that accurately predicting and measuring the reduction in infection rate is not feasible. Therefore, the target was adjusted to remove reporting on the infection reduction rate.
*** The Lancet Respiratory Medicine, Volume 3, Issue 3, March 2015, Pages 201-209 establishes the correlation between sputum culture conversion and treatment success. From the randomized clinical study (C208) SIRTURO provided a 78.8% culture conversion rate at 24 weeks versus 57.6% for placebo.
**** Percentage not inclusive of products newly recognized in 2017.
***** Total spend represents addressable spend, i.e., products and services that procurement teams can negotiate with suppliers to meet business goals.
****** We count our 28,000 active employees who completed ENERGY FOR PERFORMANCE training prior to January 1, 2016 towards progress against this target.
******* Defined as 100% implementation of policies, programs and practices for both.
More Resources
You are leaving jnj.com and entering a third party site. This link is provided for your convenience, and Johnson & Johnson disclaims liability for content created or maintained by third parties. Continue